Related Experiment Video
Updated: Sep 16, 2025
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
Published on: July 5, 2011
Microvascular Decompression for Patients With Type 1 Trigeminal Neuralgia Using Vein Sacrifice and a Teflon
Rahul Kumar1, Kathy J Stien, Bruce E Pollock
1Department of Neurologic Surgery, Mayo Clinic, Rochester , Minnesota , USA.
Background And Objectives:
Microvascular decompression (MVD) is accepted as the most effective surgery for patients with trigeminal neuralgia (TN), but controversy remains regarding operative technique.
Methods:
A prospective registry of 523 patients undergoing MVD for unilateral Type 1 TN from July 1999 through September 2022 was reviewed. Patients with Type 2 TN, secondary TN, bilateral TN, vertebrobasilar compression, or previous MVD were excluded. The goal at surgery was to have nothing contacting the trigeminal nerve: arteries in contact with the trigeminal nerve were mobilized away from the nerve root whenever possible and secured with Teflon whereas veins in contact with the trigeminal nerve were sacrificed. Partial sensory rhizotomy was performed if the vascular compression was insignificant or no vascular compression was noted. The primary outcome was pain-free survival without medications. The median follow-up after surgery was 8.2 years.
Results:
More patients were women (n = 310, 59.3%), the median age was 63 years, the median pain duration was 5 years, and 110 patients (21.0%) had previous ablative procedures. Operative technique was arterial transposition (n = 255, 48.8%), arterial transposition and vein sacrifice (n = 182, 34.8%), vein sacrifice (n = 64, 12.2%), and partial sensory rhizotomy (n = 22, 4.2%). Initially, 485 patients (92.7%) were pain-free without medications. Pain-free survival estimates at 5, 10, and 15 years were 77.6%, 72.5%, and 69.7%, respectively. Women (hazards ratios = 1.48, P = .03) had a lower rate of pain-free survival. Eighty-three patients (15.9%) had postoperative complications; the most common was new facial numbness (n = 37, 7.1%). Three patients (0.6%) had venous infarctions, and 2 patients (0.4%) had reported Teflon granulomas.
Conclusion:
A noncompressive MVD using vein sacrifice, arterial transposition whenever possible, and Teflon implantation provided long-term pain relief for most patients with Type 1 TN with a low risk of venous infarction or Teflon granuloma formation.
